Biolinq Incorporated, a medical device company developing a continuous glucose sensor with a novel integrated display on its wearable device, has announced the closing of a $100 million Series B financing round led by RiverVest Venture Partners.

Biolinq has developed a micro-array of biosensors to measure interstitial fluid glucose levels just under the surface of the skin, leveraging innovation from the semiconductor industry to miniaturize electrochemical sensors designed for precision manufacturing and significant scale. “Biolinq is a genuine game-changer – with a product platform designed to make continuous sensing simple and more accessible. Biolinq is a medical device company developing a wearable biosensor platform that measures biomarkers important to the management of many clinical conditions, including diabetes.

Biolinq Raises $100 Million, Unveils Micro-Sensing Technology In The Skin

Description

Company Information

Funding Insights

Biolinq Raises $100 Million, Unveils Micro-Sensing Technology In The Skin

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information